George Papaliodis is an Ophthalmology physician affiliated with Massachusetts Eye and Ear Infirmary. OpenAlex indexes 123 publications with 2,262 citations (h-index 25); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
243 Charles St
Boston, MA 021143002
Telephone
617-573-4169Registry record last updated 5 Jan 2009.
Clinical trials
- PEMF: an Adjunct Therapy for Anterior Uveitis
Sponsor: Massachusetts Eye and Ear Infirmary
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- SANOFI US SERVICES INC.Program year20241 payment
- SANOFI US SERVICES INC.Program year20232 payments$16,001openpaymentsdata.cms.gov ↗
- EyePoint Pharmaceuticals US, Inc.Program year20221 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
65.2%Corticosteroid29.7%Prednisolone Acetate94%Fluorometholone7%Part D≥165 patientsalpha-Adrenergic Agonist10.4%Brimonidine Tartrate100%Part D≥51 patients+ 5 more classes in this area
Anti-infectives
11.5%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor4.4%Valacyclovir100%Part D≥31 patientsMacrolide3.2%Erythromycin100%Part D≥19 patients+ 2 more classes in this area
Musculoskeletal
10.7%Cyclooxygenase Inhibitor9.8%Ketorolac Tromethamine100%Part D≥59 patientsNonsteroidal Anti-inflammatory Drug1%Naproxen100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Consensus disease definitions for ophthalmic immune-related adverse events of immune checkpoint inhibitors
Journal for ImmunoTherapy of Cancer
2025 - Restoration of Vision in Severe, Cicatricial, Ocular Surface Disease With the Boston Keratoprosthesis Type II
American Journal of Ophthalmology
2022 - High Positive Predictive Value of Fluorescein Angiography Contiguous, Perineural Retinal Vascular Leakage Pattern for Birdshot Chorioretinopathy
Ocular Immunology and Inflammation
2022
Similar KOLs
Other experts from the same institution or the same specialty.
Dean Eliott, MD
Massachusetts Eye and Ear Infirmary
Leo Kim, MD
Massachusetts Eye and Ear Infirmary
Daniel Liebman, MD
Massachusetts Eye and Ear Infirmary
Reza Dana, MD, MSE, MPH
Massachusetts Eye and Ear Infirmary
Emily Chew, MD
National Eye Institute
Robert Weinreb, MD
University of California San Diego
Harry Quigley, MD
Johns Hopkins University School of Medicine
Joel Schuman, MD
Wills Eye Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”